March 05, 2026 a 04:38 pm
CAH: Analysts Ratings - Cardinal Health, Inc.
The stock of Cardinal Health, Inc. (CAH) has shown a consistent preference toward 'Buy' and 'Strong Buy' ratings from analysts in recent months. This reflects a positive sentiment in the healthcare and pharmaceutical sectors that the company operates in. Despite a challenging macroeconomic environment, Cardinal Health has maintained steady growth, largely driven by its diversified service offerings and robust market position. The stable analyst ratings signify sustained confidence in the company's strategic direction and financial health.
Historical Stock Grades
As of March 2026, Cardinal Health has maintained a strong analyst consensus. The persistent 'Buy' and 'Strong Buy' recommendations indicate a general belief in the company's ongoing potential for growth and value creation.
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 11 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
In recent months, Cardinal Health has seen a remarkable consistency in its analyst ratings. Despite micro and macroeconomic challenges, the number of 'Buy' recommendations has predominated, reflecting a strong market sentiment:
- The number of 'Strong Buy' ratings has remained steady over the past year, highlighting enduring optimism despite potential market volatility.
- 'Hold' ratings have slightly fluctuated, suggesting cautious optimism but no significant negative outlook.
- Overall, there is a trend towards maintaining current ratings, indicating stability in market sentiment.
Percentage Trends
The analyst ratings for Cardinal Health demonstrate a persistent focus on 'Buy' recommendations. This indicates market confidence despite minor swings in other categories:
- The proportion of 'Buy' recommendations remained approximately 60% for the past several months.
- 'Hold' ratings have held around 20-25%, with only slight variations.
- The absence of 'Sell' or 'Strong Sell' ratings in recent months underscores faith in the company's strategic outlook.
- Overall, a slight increase in 'Buy' ratings has been observed, showing increased confidence in company performance.
Latest Analyst Recommendations
The most recent analyst recommendations have been consistent, with no changes in ratings, further supporting the stable outlook for Cardinal Health:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-24 | Overweight | Overweight | Barclays |
| 2026-02-10 | Neutral | Neutral | JP Morgan |
| 2026-02-10 | Overweight | Overweight | Wells Fargo |
| 2026-02-06 | Outperform | Outperform | Mizuho |
| 2026-01-29 | Overweight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Recent upgrades highlight a moderate shift in analyst opinion, indicating renewed confidence in Cardinal Health's potential:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-09 | Buy | Neutral | Citigroup |
| 2025-06-03 | Overweight | Equal Weight | Wells Fargo |
| 2025-02-05 | Buy | Hold | Jefferies |
| 2025-01-08 | Buy | Hold | TD Cowen |
| 2025-01-07 | Outperform | In Line | Evercore ISI Group |
Interpretation
Analysts’ consistent ratings for Cardinal Health suggest strong faith in its current business strategy and future growth potential. The upgrades indicate a shift towards more favorable opinions, though the stability of the ratings also implies no significant surprises in stock performance. The absence of negative sentiment and the presence of recent upgrades reflect growing confidence in its market stance, with stability as a key theme.
Conclusion
Cardinal Health has demonstrated steady market confidence through consistent 'Buy' and 'Overweight' ratings, underlining its strategic robustness and growth in the competitive healthcare marketplace. The observed stability in analyst ratings points to a well-managed company with a secure market position, although ongoing vigilance over market and economic conditions is advisable to capitalize on further opportunities or preempt risks.